1 / 21

Xtandi 40mg - Anticancer drugs | view uses, side effects and price | MHP

Enzalutamide is an active ingredient of Xtandi tablets available in the strength of 40mg. Xtandi 40mg tablets are used to treat the metastatic prostate cancer in men @MHP

veronicaAndrews
Télécharger la présentation

Xtandi 40mg - Anticancer drugs | view uses, side effects and price | MHP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ENZALUTAMIDE 40MG

  2. DESCRIPTION • Xtandicontaining Enzalutamide is also categorized as an anti-androgen chemo medicine. Xtandi 40mg is not self medication; it is used under the knowledge of medical oncologist.

  3. XTANDI 40MG TABLET USES • Xtandi 40mg tablets are prescribing for; Metastatic or long lasting castration resistant prostate cancer

  4. XTANDI 40MG TABLET MECHANISM • Xtandi 40mg containing anti-androgen agent like Enzalutamide, it expels an anti-tumor activity in different steps. Xtanditablets are interfere in androgen receptor signaling pathway, which prohibiting androgen binding to androgen receptors leads to androgen receptor nuclear translocation inhibition and interact with DNA.

  5. The major metabolite of Xtandiis N-desmethylEnzalutamide which is similar to Enzalutamide activity. The anti-tumor activity of Xtandiis exposed by depleting the multiplication and persuades cell lysis in prostate cancer cells.

  6. PHARMACOKINETICS • After an oral administration of Xtandi 40mg tablets (160mg of dose), undergoes ADME process and exhibits activity. The peak plasma concentration time of Xtandi occurs at 1 hour with the range of 0.5 to 3 hours). The steady state of Xtandioccurs in day 28. The volume of distribution occur after single dose of Xtandi is 110LXtandi has highly bounds to the human plasma protein with the range of 97 to 98%. 

  7. The major metabolite of Enzalutamide is N-desmethylEnzalutamide has 95% bound to human plasma protein. The most important isoenzymes responsible for the metabolism of Enzalutamide are CYP2C8 & CYP3A4. CYP2C8 is involved in the formation of an active metabolite N-desmethylEnzalutamide. Xtandiis majorly excreted through liver metabolism, 71% of metabolite present in urine and 14% in feces.

  8. DOSAGE MANAGEMENT The usual recommended dosage of Xtandiis 160mg, but available strength of Xtandiis 40mg. Four tablets of Xtandi 40mg should be taken at a time as a single dose.Xtanditablet should be administered with or without food. Dosing alteration: In ≥ grade 3 toxicity or extreme side effects: Postpone the dose ofXtandifor 1 week or as far as symptoms progress to ≤ grade 2, continue at the same or reduced to 120mg or 80mg.

  9. In case of combination with strong CYP2C8 inhibitors, diminish the dose of Xtandito 80mg as a single dose. Concurrent use with strong CYP3A4 inducers: In case of combination with strong CYP3A4 inducers, increasing the dose of Xtandi160mg to 240mg as a single dose. • Concurrent use with strong CYP2C8 inhibitors: • In case of combination with strong CYP2C8 inhibitors, diminish the dose of Xtandito 80mg as a single dose. Concurrent use with strong CYP3A4 inducers: In case of combination with strong CYP3A4 inducers, increasing the dose of Xtandi160mg to 240mg as a single dose.

  10. PRECAUTIONS • XTANDI 40MG TABLETS SAFETY PRECAUTIONS • The major adverse effect during the therapy of Xtanditablets are; • SEIZURE Seizure may produce during the treatment with Xtanditablets, if seizure occurs the treatment should be discontinued until seizure resolved. To avoid this condition,

  11. patient should be counsel about the problems occurred during the therapy before starting the treatment. Seizure may leads to loss of consciousness.  • POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME PRES  Patient who are all taking Xtanditablets acquired PRES, is a neurological problem produce symptoms like headache, lethargy, confusion, loss of vision, other neurological problems related with hypertension.

  12. SIDE EFFECTS • XTANDI 40MG TABLETS CAUSING SIDE EFFECTS • Asthenia • Peripheral edema • Back pain, arthralgia • Musculoskeletal pain • Muscular weakness • Musculoskeletal stiffness

  13. Diarrhea • Headache • Dizziness • Spinal cord compression • Caude equine syndrome • Paresthesia • Mental disorders • Hypoesthesia • Respiratory tract infections

  14. Hot flush • Hypertension • Insomnia • Anxiety • Hematuria • Pollakiuria • Non pathologic fractures • Pruritus Dry skin • Epistaxis

  15. PREGNANCY & LACTATION: The pregnancy category of Xtanditablet is X Xtanditablets are contraindicated to pregnancy conditions; it may cause fetal harm even to death. Xtanditablets are contraindicated in lactation period, breast feeding should not be recommended.

  16. STORAGE • The storage condition of Xtanditablets container at 20°C to 25°C (68°F to 77°F). Container should be kept at dry and cool place.

  17. MISSED DOSE • Xtandiis a chemo tablets, if patient fail to take the dose of Xtanditablets must be consult with medical oncologist and take the dose within a time. In any other way the missed dose should be avoid and follow the regular dosing schedule.

  18. OVER DOSAGE • In case of over dosage of Xtanditablets, patients must provided with some supportive measures and discontinue the therapy. The half life of Xtandiis occurs for 5.8 days. Seizure is the major adverse effect occurred due to over dosage of Xtandi. Seizure is not described at ≤240mg daily; since three seizures occurs at 360mg, 480mg and 600mg daily.

  19. THANK YOU

More Related